Education
About Us
Working with TipRanks
Follow Us
InflaRx NV (IFRX)
NASDAQ:IFRX
IFRX Analyst Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IFRX Stock 12 Month Forecast
Average Price Target
$4.00
▲(154.78% Upside)
| Highest Price Target$6.00 | Average Price Target$4.00 | Lowest Price Target$2.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$6
Buy
282.17%
Upside
Initiated
09/02/25
InflaRx: Buy Rating Based on Promising C5a/C5aR Strategy and Strong Financial PositionValuation and risks to price target achievement. We are assuming coverage with a Buy rating and $6 price target; the prior rating was Under Review. Our price target is based on our clinical net present value (NPV) model, which derives its value from INF904 for CSU (73% contribution; 20% PoS) and HS (27% contribution; 20% PoS) in the U.S. only. We do not value the commercial sales of GOHIBIC yet because it is not a growth stage asset with projected revenue generation that has remained largely nominal.
Leerink Partners
$2
Buy
27.39%
Upside
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: Replimune Group (NASDAQ: REPL), Pliant Therapeutics (NASDAQ: PLRX) and InflaRx (NASDAQ: IFRX)We are updating our model to reflect InflaRx's (IFRX, OP) 2Q25 financial results and corporate update; focus remains on the upcoming Ph.2a readout in HS and CSU, now expected by the end of September to early November (previously summer 2025). Following the recommendation to stop the Ph.3 trial (NCT05964413) for vilobelimab (monoclonal anti-human complement factor C5a antibody) in pyoderma gangrenosum (PG) due to futility (here), the focus for the company has shifted entirely to IFRX's now lead asset INF904, an oral complement C5a receptor (C5aR) inhibitor, in development for hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU).
LifeSci Capital
―
Hold
―
Reiterated
08/07/25
Raymond James
$13→$2
Buy
27.39%
Upside
Reiterated
05/29/25
Guggenheim
$10
Buy
536.94%
Upside
Reiterated
05/28/25
Oppenheimer
$6→$3
Buy
91.08%
Upside
Reiterated
05/28/25
Cantor Fitzgerald
$10
Buy
536.94%
Upside
Initiated
04/28/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$6
Buy
282.17%
Upside
Initiated
09/02/25
InflaRx: Buy Rating Based on Promising C5a/C5aR Strategy and Strong Financial PositionValuation and risks to price target achievement. We are assuming coverage with a Buy rating and $6 price target; the prior rating was Under Review. Our price target is based on our clinical net present value (NPV) model, which derives its value from INF904 for CSU (73% contribution; 20% PoS) and HS (27% contribution; 20% PoS) in the U.S. only. We do not value the commercial sales of GOHIBIC yet because it is not a growth stage asset with projected revenue generation that has remained largely nominal.
Leerink Partners
$2
Buy
27.39%
Upside
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: Replimune Group (NASDAQ: REPL), Pliant Therapeutics (NASDAQ: PLRX) and InflaRx (NASDAQ: IFRX)We are updating our model to reflect InflaRx's (IFRX, OP) 2Q25 financial results and corporate update; focus remains on the upcoming Ph.2a readout in HS and CSU, now expected by the end of September to early November (previously summer 2025). Following the recommendation to stop the Ph.3 trial (NCT05964413) for vilobelimab (monoclonal anti-human complement factor C5a antibody) in pyoderma gangrenosum (PG) due to futility (here), the focus for the company has shifted entirely to IFRX's now lead asset INF904, an oral complement C5a receptor (C5aR) inhibitor, in development for hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU).
LifeSci Capital
―
Hold
―
Reiterated
08/07/25
Raymond James
$13→$2
Buy
27.39%
Upside
Reiterated
05/29/25
Guggenheim
$10
Buy
536.94%
Upside
Reiterated
05/28/25
Oppenheimer
$6→$3
Buy
91.08%
Upside
Reiterated
05/28/25
Cantor Fitzgerald
$10
Buy
536.94%
Upside
Initiated
04/28/25
Best Analysts Covering InflaRx
1 Month
xxx
Success Rate
7/19 ratings generated profit
Average Return
+5.32%
initiated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 36.84% of your transactions generating a profit, with an average return of +5.32% per trade.
3 Months
xxx
Success Rate
7/18 ratings generated profit
Average Return
+4.37%
reiterated a xxx
rating 30 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 38.89% of your transactions generating a profit, with an average return of +4.37% per trade.
1 Year
Success Rate
6/18 ratings generated profit
Average Return
-15.58%
reiterated a buy rating 30 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -15.58% per trade.
2 Years
xxx
Success Rate
9/18 ratings generated profit
Average Return
-6.03%
reiterated a xxx
rating 30 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -6.03% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IFRX Analyst Recommendation Trends
Rating
Apr 25
May 25
Jul 25
Aug 25
Sep 25
Strong Buy
7
13
8
8
2
Buy
1
0
0
0
0
Hold
3
5
7
11
8
Sell
1
3
3
3
2
Strong Sell
0
0
0
0
0
total
12
21
18
22
12
Each month's total comprises the sum of three months' worth of ratings.
IFRX Financial Forecast
IFRX Stock Forecast FAQ
What is IFRX’s average 12-month price target, according to analysts?
Based on analyst ratings, InflaRx NV’s 12-month average price target is 4.00.
What is IFRX’s upside potential, based on the analysts’ average price target?
InflaRx NV has 154.78% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IFRX a Buy, Sell or Hold?
InflaRx NV has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
What is InflaRx NV’s price target?
The average price target for InflaRx NV is 4.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $6.00 ,the lowest forecast is $2.00. The average price target represents 154.78% Increase from the current price of $1.57.
The highest analyst price target is $6.00 ,the lowest forecast is $2.00. The average price target represents 154.78% Increase from the current price of $1.57.
What do analysts say about InflaRx NV?
InflaRx NV’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of IFRX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.